Pembrolizumab Antitumor Activity Promises Potential for Sarcoma Subtypes
November 15th 2016
Pembrolizumab reduced the size of tumors in patients with a subtype of soft tissue sarcoma, according to updated interim results from the phase II SARC028, multicenter clinical trial, which were reported at the most recent meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.